Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
OTC Drugs

Codex Panel Backs Use Of Observational Data To Support Health Claims

This article was originally published in The Tan Sheet

  • News

Executive Summary

Regulatory agencies worldwide should consider all available scientific evidence - including epidemiological and observational studies - when evaluating the basis of health claims for products marketed internationally, a Codex committee recommends

You may also be interested in...



International Panel’s Nutrient Value Guideline May Boost Supplement Exports

Dietary supplement firms soon could export products internationally without having to reformulate to accommodate local nutrient value regulations.

International Panel’s Nutrient Value Guideline May Boost Supplement Exports

Dietary supplement firms soon could export products internationally without having to reformulate to accommodate local nutrient value regulations.

International Panel’s Nutrient Value Guideline May Boost Supplement Exports

Dietary supplement firms soon could export products internationally without having to reformulate to accommodate local nutrient value regulations.

Table

View full table

Related Content

Pink Sheet
Pink Sheet

Topics

Tags:
OTC Drugs
Latest Headlines

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

Partisan Politics Returns To US FDA Congressional Oversight

GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows

Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development

See All
UsernamePublicRestriction

Register

PS102350

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By